You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

CLINICAL TRIALS PROFILE FOR PEPCID AC


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for pepcid ac

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00451880 ↗ Study of XL281 in Adults With Solid Tumors Completed Exelixis Phase 1 2007-02-01 The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.
NCT00557349 ↗ Ulcer Prevention Study in Post Gastric Bypass Patients Completed University of Missouri-Columbia Phase 4 2006-11-01 This research is to determine which medication, Zegerid (Omeprazole/Sodium Bicarbonate) or Pepcid AC (Famotidine), works best at reducing the chance that a patient will get an ulcer after gastric bypass surgery.
NCT00256841 ↗ Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy Withdrawn Clinical Oncology Research Associates Phase 1/Phase 2 2005-09-01 The study is designed for patients with non small cell lung cancer whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer. At this stage of the disease, most patients cannot be cured from the disease, however, treatment can help to live longer and better by keeping the cancer under control. For that purpose, patients traditionally receive radiation therapy or chemotherapy or both treatments in succession. Recently, the administration of both treatment methods given concurrently showed somewhat better results when compared to successive administration. In some studies the drug Taxotere together with radiation performed well in keeping the cancer better under control. Combination of the drug Taxotere together with a compound called 5-FU either as continuous infusion or in its oral form of a pill called "Xeloda" enhanced its anti cancer activity substantially. One goal of this study is to investigate how much of the combination can be given in conjunction with chest radiation. Using X-rays, the study will also evaluate how much shrinkage of the cancer is caused by this treatment directly at the tumor site and other areas where the cancer may have also spread. In this study the radiation will be given on only one day per week in two sessions, rather than divided over five days per week (Monday through Friday) as it is more commonly used. However, both schedules have been found to be equally effective. The treatment program will use increasing doses of the 5-FU medication, either as infusion or as pill to find the highest dose that is tolerated. Once the highest tolerated dose is determined, subsequent patients who will be enrolled will continue to be treated at that dose level. The dose of the drug Taxotere will remain the same throughout. Hypothesis: Our previous research suggests that the combination of Taxotere and 5-FU given together with weekly chest radiation will provide a more convenient form of treatment than the conventional approach and also be at least similar in its efficacy.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

Clinical Trial Conditions for pepcid ac

Condition Name

5550-0.500.511.522.533.544.555.5Covid19HealthyCOVID-19[disabled in preview]
Condition Name for pepcid ac
Intervention Trials
Covid19 5
Healthy 5
COVID-19 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

733001234567COVID-19Virus DiseasesRespiratory Tract Diseases[disabled in preview]
Condition MeSH for pepcid ac
Intervention Trials
COVID-19 7
Virus Diseases 3
Respiratory Tract Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for pepcid ac

Trials by Country

+
Trials by Country for pepcid ac
Location Trials
United States 42
India 2
Canada 1
Australia 1
Jordan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for pepcid ac
Location Trials
Texas 10
New York 3
Florida 3
Arizona 3
Connecticut 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for pepcid ac

Clinical Trial Phase

71.4%14.3%14.3%0-0.500.511.522.533.544.555.5Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for pepcid ac
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

48.1%29.6%22.2%002468101214CompletedRecruitingNot yet recruiting[disabled in preview]
Clinical Trial Status for pepcid ac
Clinical Trial Phase Trials
Completed 13
Recruiting 8
Not yet recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pepcid ac

Sponsor Name

trials011223344556M.D. Anderson Cancer CenterBristol-Myers SquibbUnited States Department of Defense[disabled in preview]
Sponsor Name for pepcid ac
Sponsor Trials
M.D. Anderson Cancer Center 5
Bristol-Myers Squibb 3
United States Department of Defense 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

48.8%44.2%7.0%0-20246810121416182022OtherIndustryU.S. Fed[disabled in preview]
Sponsor Type for pepcid ac
Sponsor Trials
Other 21
Industry 19
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Pepcid ac Market Analysis and Financial Projection

Pepcid AC (Famotidine): Clinical Trials, Market Analysis, and Projections

Introduction to Pepcid AC (Famotidine)

Pepcid AC, commonly known by its generic name famotidine, is a histamine-2 (H2) receptor antagonist used to treat various gastrointestinal conditions, including gastroesophageal reflux disease (GERD), heartburn, and ulcers. Here, we will delve into the latest clinical trials, market analysis, and projections for this widely used medication.

Clinical Trials Update

COVID-19 Trials

During the COVID-19 pandemic, there was significant interest in whether famotidine could serve as a treatment for COVID-19 symptoms. A clinical trial initiated at New York’s Northwell hospitals in early 2020 aimed to determine if high doses of intravenous famotidine could reduce the severity of COVID-19 in patients. However, as of January 2022, no conclusive evidence had been found to support the effectiveness of famotidine in treating COVID-19[1].

More recent studies, such as a phase two clinical trial published in 2022, suggested that famotidine might alleviate COVID-19 symptoms by activating the vagus nerve and reducing cytokine storms. This trial, led by Northwell Health and Cold Spring Harbor Laboratory, showed promising results in improving symptoms like breathing, chest congestion, cough, and the return of taste and smell in adult patients[4].

Ongoing and Future Trials

Several clinical trials are ongoing or have been recently completed to explore various aspects of famotidine's efficacy. For example, trials sponsored by the University of Miami, Celgene, and Emory University are in different phases, focusing on different indications and dosages[3].

Market Analysis

Current Market Size and Growth

The market for gastroesophageal reflux disease (GERD) treatments, which includes famotidine, is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.3% from 2024 to 2029. This growth is driven by the rising prevalence of gastrointestinal disorders, changing lifestyles, and increasing awareness about GERD[2].

Regional Market Performance

North America currently holds the largest market share for GERD treatments, while the Asia Pacific region is expected to be the fastest-growing market over the forecast period. The increase in GERD cases due to lifestyle changes and the COVID-19 pandemic has contributed significantly to the market growth[2].

Key Players and Market Dynamics

Major players in the GERD market include Pfizer, Inc., Johnson & Johnson, Takeda Pharmaceutical Co., Ltd., and Haleon Group of Companies. The market is also seeing significant activity from generic manufacturers, which has increased the affordability and accessibility of famotidine. The shift away from proton pump inhibitors (PPIs) due to concerns over long-term side effects has further boosted the demand for famotidine[2][5].

Market Projections

Driving Factors

Several factors are expected to drive the growth of the famotidine market:

  • Rising Prevalence of Gastrointestinal Disorders: Increasing cases of acid reflux and GERD due to dietary habits and stress levels.
  • Shift from PPIs: Growing awareness of the long-term risks associated with PPIs is leading to a preference for H2 antagonists like famotidine.
  • Generic Versions: The emergence of generic alternatives is making famotidine more affordable and accessible.
  • OTC Availability: Over-the-counter (OTC) availability of famotidine has expanded its reach and convenience for consumers[5].

Challenges

Despite the positive outlook, the market faces some challenges:

  • Patent Expirations: The expiration of patents for blockbuster drugs can impact market dynamics.
  • Product Recalls: Frequent product recalls can restrain market growth.
  • Regulatory Changes: Changes in regulatory environments can affect the approval and launch of new products[2].

Recent Developments and Innovations

New Product Launches

In recent years, there have been several new product launches that have contributed to the market growth. For example, Sanofi's Consumer Healthcare launched a new OTC medication, Zantac 360°, with famotidine as the active ingredient in April 2021[2].

Advanced Treatment Options

The development of new treatment centers and the introduction of minimally invasive procedures, such as those offered by the Heartburn & Reflux Center at Medical City Frisco, are also driving market growth. These advancements include transoral incisionless fundoplication (TIF) and other laparoscopic treatments for GERD and oesophageal disorders[2].

Key Takeaways

  • Clinical Trials: While early trials on famotidine's efficacy in treating COVID-19 were inconclusive, recent studies suggest it may alleviate symptoms by activating the vagus nerve.
  • Market Growth: The GERD treatment market, including famotidine, is projected to grow at a CAGR of 4.3% from 2024 to 2029.
  • Driving Factors: Rising prevalence of gastrointestinal disorders, shift from PPIs, generic versions, and OTC availability are key drivers.
  • Challenges: Patent expirations, product recalls, and regulatory changes are potential restraints.

FAQs

What is the current status of famotidine in treating COVID-19?

As of the latest updates, while some studies suggest famotidine may alleviate COVID-19 symptoms, there is no conclusive evidence to support its widespread use as a treatment for COVID-19[1][4].

Which region is expected to be the fastest-growing market for GERD treatments?

The Asia Pacific region is expected to be the fastest-growing market for GERD treatments over the forecast period[2].

What are the main drivers of the famotidine market?

The main drivers include the rising prevalence of gastrointestinal disorders, a shift away from PPIs, the availability of generic versions, and OTC availability[5].

Who are the major players in the GERD market?

Major players include Pfizer, Inc., Johnson & Johnson, Takeda Pharmaceutical Co., Ltd., and Haleon Group of Companies[2].

What are the potential challenges facing the famotidine market?

Challenges include patent expirations, product recalls, and changes in regulatory environments[2].

Sources

  1. Can Pepcid treat COVID-19? - C&EN - American Chemical Society
  2. Gastroesophageal Reflux Disease Market Size & Share Analysis - Mordor Intelligence
  3. Generic FAMOTIDINE INN equivalents, drug patent and freedom to operate - Drug Patent Watch
  4. Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19 - BioSpace
  5. Famotidine (Pepcid) Manufacturing Plant Project Report 2024 - IMARC Group

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.